Eli Lilly To Buy Ajax Therapeutics To Advance AJ1-11095 Development
27/4 13:19
(RTTNews) - Eli Lilly and Company (LLY), Monday announced a deal with Ajax Therapeutics, Inc., agreeing to acquire the company along with its lead asset, AJ1-11095, an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in patients wi...